rs63751175

Variant summary

Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBS2_Supporting

The NM_000518.5(HBB):​c.316-125A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000286 in 921,806 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.00042 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00026 ( 2 hom. )

Consequence

HBB
NM_000518.5 intron

Scores

2

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:1U:1B:7

Conservation

PhyloP100: -0.172
Variant links:
Genes affected
HBB (HGNC:4827): (hemoglobin subunit beta) The alpha (HBA) and beta (HBB) loci determine the structure of the 2 types of polypeptide chains in adult hemoglobin, Hb A. The normal adult hemoglobin tetramer consists of two alpha chains and two beta chains. Mutant beta globin causes sickle cell anemia. Absence of beta chain causes beta-zero-thalassemia. Reduced amounts of detectable beta globin causes beta-plus-thalassemia. The order of the genes in the beta-globin cluster is 5'-epsilon -- gamma-G -- gamma-A -- delta -- beta--3'. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -5 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.81).
BS2
High Homozygotes in GnomAdExome4 at 2 SD geneVariant has number of homozygotes lower than other variant known as pathogenic in the gene, so the strength is limited to Supporting.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
HBBNM_000518.5 linkc.316-125A>G intron_variant Intron 2 of 2 ENST00000335295.4 NP_000509.1 P68871D9YZU5

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
HBBENST00000335295.4 linkc.316-125A>G intron_variant Intron 2 of 2 1 NM_000518.5 ENSP00000333994.3 P68871
HBBENST00000647020.1 linkc.316-125A>G intron_variant Intron 2 of 2 ENSP00000494175.1 P68871
HBBENST00000475226.1 linkn.248-125A>G intron_variant Intron 1 of 1 2
HBBENST00000633227.1 linkn.*132-125A>G intron_variant Intron 2 of 2 3 ENSP00000488004.1 A0A0J9YWK4

Frequencies

GnomAD3 genomes
AF:
0.000421
AC:
64
AN:
152198
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.000386
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00209
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000162
Gnomad OTH
AF:
0.00239
GnomAD4 exome
AF:
0.000260
AC:
200
AN:
769490
Hom.:
2
AF XY:
0.000222
AC XY:
90
AN XY:
405874
show subpopulations
Gnomad4 AFR exome
AF:
0.0000500
Gnomad4 AMR exome
AF:
0.00191
Gnomad4 ASJ exome
AF:
0.000384
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.000158
Gnomad4 OTH exome
AF:
0.000884
GnomAD4 genome
AF:
0.000420
AC:
64
AN:
152316
Hom.:
0
Cov.:
33
AF XY:
0.000443
AC XY:
33
AN XY:
74488
show subpopulations
Gnomad4 AFR
AF:
0.000385
Gnomad4 AMR
AF:
0.00209
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000162
Gnomad4 OTH
AF:
0.00236
Alfa
AF:
0.000427
Hom.:
0
Bravo
AF:
0.000771

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:1Benign:7
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:1Benign:3
Mar 12, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jun 14, 2019
GeneDx
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is associated with the following publications: (PMID: 30047296, 21423179, 18976160, 27258795, 24401016, 17994377, 29171316) -

Aug 16, 2021
Revvity Omics, Revvity
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Oct 07, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

beta Thalassemia Pathogenic:1Benign:1
Nov 25, 2019
The ITHANET community portal, The Cyprus Institute of Neurology and Genetics
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: curation

- -

Sep 16, 2020
Natera, Inc.
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

not specified Benign:2
Feb 27, 2020
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Apr 02, 2024
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: HBB c.316-125A>G is located at a position not widely known to affect splicing. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00029 in 921806 control chromosomes in the gnomAD database, including 2 homozygotes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. The variant, c.316-125A>G, has been reported in the literature in a homozygous patient from a consanguineous family presenting with BTHAL-ITMD (Agouti_2007). However, recent studies identified this variant in heterozygosity in multiple individuals with normal hematological and electrophoretic features, in a healthy alpha-thalassemia carrier together with an alpha deletion, in a healthy beta-thalassemia carrier in compound heterozygosity with HBB c.93+1G>A (Vinciguerra_2017, Grimholt_2018), and in a healthy individual in compound heterozygosity with the pathogenic HBB c.364G>C (Hb D-Punjab). All studies classified the variant as a polymorphism due to the carriers having the expected phenotypes given their genotypes. The following publications have been ascertained in the context of this evaluation (PMID: 18976160, 17994377, 33851260, 21423179, 30047296, 20113284, 29171316). ClinVar contains an entry for this variant (Variation ID: 439149). Based on the evidence outlined above, the variant was classified as likely benign. -

HBB-related disorder Benign:1
Jun 09, 2022
PreventionGenetics, part of Exact Sciences
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.81
CADD
Benign
0.95
DANN
Benign
0.69

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs63751175; hg19: chr11-5247081; API